Views: 0 Author: Site Editor Publish Time: 2025-07-29 Origin: Site
CAS No. 143782-23-4, known chemically as Tenofovir alafenamide hemifumarate (TAF hemifumarate), is a crucial intermediate and active component in the manufacturing of the antiretroviral drug Tenofovir alafenamide (TAF). TAF is a prodrug of Tenofovir, widely used in the treatment of HIV/AIDS and chronic hepatitis B.
Compared to its predecessor, Tenofovir disoproxil fumarate (TDF), TAF has improved safety and efficacy at a significantly lower dose. The intermediate represented by CAS 143782-23-4 is critical in the final stages of TAF synthesis.
Enables enhanced delivery of Tenofovir with reduced renal and bone toxicity.
Included in key combination drugs like Biktarvy and Genvoya.
Must meet strict GMP and ICH Q7 guidelines for impurity control and stereoselectivity.
Global drug authorities (FDA, EMA, WHO) demand full traceability and validated processes.
Used in global HIV treatment programs by NGOs and public health organizations.
Location: California, USA
Overview: The original patent holder and primary manufacturer of TAF. Supplies intermediates through licensed partners.
Specialty: Originator with strict quality and IP compliance.
Location: Barcelona, Spain
Overview: Manufactures advanced intermediates and APIs for antiretroviral drugs, with European GMP certification.
Specialty: Expertise in phosphonate chemistry and custom synthesis.
Location: Changzhou City, Jiangsu Province, China
Overview: A reliable global supplier of antiviral intermediates, including CAS 143782-23-4, offering competitive pricing and export-ready compliance.
Specialty: High-purity, cost-effective production with full technical dossier support.
Location: Hyderabad, India
Overview: Offers integrated CDMO services with a strong focus on HIV intermediates and prodrugs.
Specialty: Advanced process chemistry and regulatory support.
Location: Milan, Italy
Overview: Leading manufacturer of high-potency antiviral intermediates with state-of-the-art containment.
Specialty: Compliance with EU, US, and global regulatory standards.
Location: Mumbai, India
Overview: Major global generic manufacturer with vertically integrated production of TAF and related intermediates.
Specialty: WHO-prequalified production with access to low-income markets.
Location: New York, USA
Overview: CDMO providing high-quality intermediates and APIs for antivirals and specialty pharma.
Specialty: Custom route development and scale-up capabilities.
Location: Maharashtra, India
Overview: Manufactures nucleotide and phosphoramidate intermediates for HIV treatment.
Specialty: Efficient, scalable synthesis under cGMP.
Location: Montreal, Canada
Overview: Produces TAF intermediates for regulated markets under North American GMP standards.
Specialty: Focus on purity, impurity profiling, and batch consistency.
Location: Milan, Italy
Overview: A well-established European API/intermediate manufacturer offering contract production for antiviral intermediates.
Specialty: Custom manufacturing with analytical and regulatory services.
Lower toxicity and improved efficacy are driving a shift from TDF to TAF in HIV care.
Companies in India and other markets are increasingly licensed to produce and distribute TAF.
Demand for competitively priced intermediates like CAS 143782-23-4 is rising across public health procurement.
High-purity and impurity control are critical for ensuring the safety and efficacy of antiretrovirals.
Eco-friendly methods and green chemistry approaches are gaining traction in phosphonate and nucleotide synthesis.
CAS No. 143782-23-4 plays a central role in the synthesis of Tenofovir alafenamide, a key player in modern HIV and HBV treatment. With experienced manufacturers like Eastfine, Farmhispania, Olon, and Sai Life Sciences, the global supply of this intermediate remains strong, consistent, and compliant with regulatory standards.
As the world continues to battle viral infections with advanced therapies, reliable suppliers of intermediates like this will be vital to scaling access and improving health outcomes across regions.
简体中文
